Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems reported impressive growth in its fiscal third quarter ending October 31, 2020, with total revenues reaching $377.5 million, a 34% increase year-over-year. Subscription services revenues also rose 34% to $302.9 million. Operating income was $101.3 million, up 25%, while net income increased 18% to $97.0 million. The company provided guidance for Q4 revenues of $378-$380 million and fiscal year revenues of $1.446-$1.448 billion. Veeva emphasized ongoing digital transformation in life sciences as a driver of growth.
Veeva Systems (NYSE: VEEV) announced that Bristol Myers Squibb (NYSE: BMY) will adopt Veeva Vault PromoMats for enhanced content delivery across digital channels. This application enables automatic generation of submission-ready forms for products, streamlining the process to meet FDA eCTD requirements. The new capability is expected to launch in December 2020, which will improve compliance and accelerate promotional material packaging for Bristol Myers Squibb. This partnership builds on Veeva's existing solutions, enhancing customer engagement and regulatory compliance.
Veeva Systems (NYSE: VEEV) has expanded its Veeva Link offering to include 11 new therapeutic areas, enhancing real-time customer intelligence for life sciences teams. The new areas cover diverse fields such as cardiology, dermatology, and neurology, building on the success of Veeva Link for Oncology, which is utilized by 6 of the top 10 pharmaceutical companies. The solutions are set to be available in March 2021, leveraging over 50,000 sources for accurate data on healthcare decision-makers.
Veeva Systems (NYSE: VEEV) announced the expansion of Veeva Link to include 11 new therapeutic areas: bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology. This enhancement aims to provide commercial and medical teams with real-time customer intelligence. Veeva Link is already utilized by six of the ten largest pharmaceutical companies, focusing on improved engagement with healthcare decision-makers. The new solutions are expected to be available in March 2021.
Veeva Systems (NYSE: VEEV) announced that Bristol Myers Squibb (NYSE: BMY) will implement Veeva Vault PromoMats to enhance their promotional material process. This new capability, available in December 2020, allows for automatic generation of submission-ready forms, streamlining the approval process with the U.S. FDA. Vault PromoMats combines digital asset management with regulatory compliance to ensure efficient content distribution. This partnership aims to support Bristol Myers Squibb's needs for faster and compliant content delivery.
Veeva Systems reports that over 75 organizations, including top pharmaceutical companies, are adopting Veeva Vault CTMS to enhance clinical trial efficiency and speed. This modern cloud application is now managing nearly 50,000 clinical trials, facilitating real-time insights and proactive management. The platform integrates with Veeva Vault EDC and includes new capabilities like Vault Payments, allowing for better collaboration and compliance. The focus on streamlining operations aims to mitigate delays and improve overall study execution.
Summary not available.
Summary not available.
Axsome Therapeutics has partnered with Veeva Systems to enhance its Digital-Centric Commercialization (DCC™) platform, aimed at optimizing marketing for CNS drugs AXS-05 and AXS-07, expected to launch next year. Veeva will provide technology, data, and consulting support, leveraging its Commercial Cloud products to improve physician-patient engagement.
The partnership underscores a significant shift in commercial strategy, focusing on innovative digital tools to streamline drug promotion and improve patient care.
Veeva Systems (NYSE: VEEV) announced the participation of Dr. Francesca Domenech Wuttke and Alessandro de Luca as keynote speakers at the 2020 Veeva Commercial & Medical Summit Online, Europe. The event, featuring over 80 sessions, focuses on digital transformation in life sciences to expedite drug market entry. Notable discussions include insights from Alexion, Boehringer Ingelheim, Lundbeck Italy, and Shionogi on advancing digital strategies. Scheduled for November 17-18, 2020, the summit aims to unite over 3,000 professionals from more than 250 companies in the sector.